40 research outputs found
Resonance Fluorescence Spectrum of a Trapped Ion Undergoing Quantum Jumps
We experimentally investigate the resonance fluorescence spectrum of single
171Yb and 172Yb ions which are laser cooled to the Lamb-Dicke regime in a
radiofrequency trap. While the fluorescence scattering of 172Yb is continuous,
the 171Yb fluorescence is interrupted by quantum jumps because a nonvanishing
rate of spontaneous transitions leads to electron shelving in the metastable
hyperfine sublevel 2D3/2(F=2). The average duration of the resulting dark
periods can be varied by changing the intensity of a repumping laser field.
Optical heterodyne detection is employed to analyze the fluorescence spectrum
near the Rayleigh elastic scattering peak. It is found that the stochastic
modulation of the fluorescence emission by quantum jumps gives rise to a
Lorentzian component in the fluorescence spectrum, and that the linewidth of
this component varies according to the average duration of the dark
fluorescence periods. The experimental observations are in quantitative
agreement with theoretical predictions.Comment: 14 pages including 4 figures, pdf file, fig.1 replace
Biomass equations for forest regrowth in the eastern Amazon using randomized branch sampling
Glutamine synthetase and glutamate synthase activities in relation to nitrogen fixation in Lotus spp.
Single-Domain Amnestic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study
Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old
Human papillomavirus (HPV) infection can lead to significant disease in males, including anogenital warts, intraepithelial neoplasias, and several types of oral and anogenital cancers. The quadrivalent HPV (type 6/11/16/18) L1 virus-like particle (VLP) vaccine (qHPV vaccine; Gardasil) has recently been demonstrated to prevent persistent infection and associated disease related to vaccine HPV types in males. We report the overall immunogenicity results from a trial of the quadrivalent HPV vaccine in males. Overall, 3,463 heterosexual men and 602 men who had sex with men were enrolled into a randomized, placebo-controlled, double-blind safety, immunogenicity, and efficacy study. Serum samples were collected prior to vaccination at day 1 and at months 7, 24, and 36 postvaccination. Immunogenicity was evaluated with a multiplex, competitive Luminex immunoassay. Almost all subjects (97.4 to 99.2%) seroconverted for vaccine HPV types by month 7. At month 36, 88.9%, 94.0%, 97.9%, and 57.0% of subjects were still seropositive for HPV-6, -11, -16, and -18, respectively. For all vaccine HPV types, black subjects had significantly higher antibody titers at month 7 than did both Caucasian and Asian subjects. An anamnestic antibody response was seen in men seropositive before vaccination. The vaccine was highly immunogenic in males 16 to 23 years of age; responses were comparable to those observed in women. Furthermore, the immune responses were consistent with the established efficacy of the vaccine in the prevention of incident and persistent HPV infection, anogenital warts, and anal intraepithelial neoplasia. Copyright © 2012, American Society for Microbiology. All Rights Reserved